Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|6|1793-1797

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.6, 2015-06, pp. : 1793-1797

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

By  

HEPATOLOGY, Vol. 61, Iss. 3, 2015-03 ,pp. : 769-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 79-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 129-134

John Wiley & Sons Inc

Access to resources Recommend Favorite